Abstract Number: Esoc2026ys97 Ischemic Stroke in Patients With Tumor Disease - Clinical Characteristics, Recurrence Rate, and Outcome After Mechanical Thrombectomy

Abstract Background and aims Patients with malignant diseases have an increased risk of ischemic stroke due to tumor-associated hypercoagulability, paraneoplastic mechanisms, and therapy-related vascular changes. Although mechanical thrombectomy (MT) is an established treatment for large vessel occlusion, patients with cancer have been underrepresented in randomized controlled trials, leading to limited evidence for this specific population. The primary aim of this study is to describe clinical, oncological, and interventional characteristics of cancer patients with ischemic stroke treated with MT and to evaluate functional outcomes. Secondary aims include exploratory analyses of associations between tumor characteristics, stroke recurrence, oncological course, and predictors of mortality and unfavorable outcome. Methods This monocentric, retrospective cohort study was conducted at Heidelberg University Hospital. We included 257 consecutive patients with ischemic stroke and confirmed malignant disease who underwent MT between 2007 and 2024. Collected variables included demographic data, vascular risk factors, stroke severity assessed by the NIHSS, occlusion site, interventional parameters (e.g., eTICI score), oncological characteristics, and functional outcomes measured by the modified Rankin Scale (mRS) at discharge and at 90 days. Statistical analyses comprise ordinal logistic regression for mRS shift analysis, Kaplan-Meier survival analyses, and multivariable regression models to identify predictors of mortality and unfavorable outcome. Results Data collection has been completed and statistical analyses are currently ongoing. Results will describe technical feasibility, functional outcomes, and mortality after MT in patients with malignancy, with particular emphasis on the impact of oncological and clinical characteristics. The findings aim to support evidence-based clinical decision-making in this complex patient population. Conflict of interest Gabriele Maliandi: nothing to disclose, Martin Bendszus: nothing to disclose, Markus Möhlenbruch: nothing to disclose, Sophia Hohenstatt: nothing to disclose, Noah Bahce: nothing to disclose